Loncastuximab
Based on 2 publication(s) in Google Scholar
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).
For research use only. We do not sell to patients.
- Purity : 99.50%
- CAS No.: 1875032-68-0
- Molecular Weight:144.46 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
CD19
In Vitro
ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CD19 (red) with Loncastuximab (anti-CD19) (HY-P99711). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
CAS No. 1875032-68-0
-
Accession P15391
-
Synonyms RB4v1.2
-
Molecular Weight 144.46 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.50%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Chromatogr A
Comprehensive evaluation of the analytical toolbox for commercial cysteine-linked antibody-drug conjugates. [Abstract]2026 Jun 21:1777:466966. PMID: 41962243 -
Purity & Documentation
References
[1]. Zinzani PL, et al. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022 Jan;148(1):177-190. [Content Brief]
[2]. Hess B, et al. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS J. 2021 Dec 10;24(1):11. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)